Hepatitis C virus vaccines in the era of new direct-acting antivirals

Expert Review of Gastroenterology and Hepatology

Volumn 7, Issue 2, 2013, Pages 171-185

  Shi, Chao ^a   Ploss, Alexander ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

Author keywords

antiviral immunity; hepatitis C; hepatitis C virus; vaccine development; viral diversity; viral hepatitis

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; BOCEPREVIR; DNA VACCINE; HEPATITIS C VACCINE; PEGINTERFERON; RIBAVIRIN; TELAPREVIR;

ADAPTIVE IMMUNITY; ANTIVIRAL THERAPY; CELLULAR IMMUNITY; DRUG COST; DRUG RESPONSE; HEPATITIS C; HUMAN; HUMORAL IMMUNITY; IMMUNOGENICITY; INCIDENCE; INFECTION PREVENTION; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; NONHUMAN; PASSIVE IMMUNIZATION; PREVALENCE; REVIEW; VACCINATION; VIRUS IMMUNITY;

ANIMALS; ANTIVIRAL AGENTS; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; EPITOPES; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HETEROZYGOTE; HUMANS; IMMUNITY, INNATE; T-LYMPHOCYTES; VIRAL HEPATITIS VACCINES; WORLD HEALTH;

EID: 84873112056     PISSN: 17474124     EISSN: 17474132     Source Type: Journal    
DOI: 10.1586/egh.12.72     Document Type: Review

References (159)

1. Hoofnagle JH, Mullen KD, Jones DB et al. Treatment of chronic non-A,non-B hepatitis with recombinant human alpha interferon. A preliminary report. N. Engl. J. Med. 315(25), 1575-1578 (1986). (Pubitemid 17055392)
2. Fried MW, Shiffman ML, Reddy KR et al. Peginterferon α-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 347(13), 975-982 (2002).
3. Manns MP, McHutchison JG, Gordon SC et al. Peginterferon α-2b plus ribavirin compared with interferon α-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358(9286), 958-965 (2001). (Pubitemid 32913521)
4. McHutchison JG, Everson GT, Gordon SC et al.; PROVE1 Study Team. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N. Engl. J. Med. 360(18), 1827-1838 (2009).
5. Jacobson IM, McHutchison JG, Dusheiko G et al.; ADVANCE Study Team. Telaprevir for previously untreated chronichepatitis C virus infection. N. Engl. J. Med. 364(25), 2405-2416 (2011).
6. Poordad F, McCone J Jr, Bacon BR et al.; SPRINT-2 Investigators. Boceprevir for untreated chronic HCV genotype 1 infection. N. Engl. J. Med. 364(13), 1195-1206 (2011).
7. Kwo PY, Lawitz EJ, McCone J et al.; SPRINT-1 investigators. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon α-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre Phase 2 trial. Lancet 376(9742), 705-716 (2010).
8. Lok AS, Gardiner DF, Lawitz E et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N. Engl. J. Med. 366(3), 216-224 (2012).
9. Gane EJ, Roberts SK, Stedman CA et al. Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 376(9751), 1467-1475 (2010).
10. Chayama K, Takahashi S, Toyota J et al. Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders. Hepatology 55(3), 742-748 (2012).
11. Alter MJ. Epidemiology of hepatitis C. Hepatology 26(3 Suppl. 1), 62S-65S (1997). (Pubitemid 27388074)
12. Kershenobich D, Razavi HA, Cooper CL et al. Applying a system approach to forecast the total hepatitis C virus-infected population size: model validation using US data. Liver Int. 31(Suppl. 2), 4-17 (2011).
13. Volk ML, Tocco R, Saini S, Lok AS. Public health impact of antiviral therapy for hepatitis C in the United States. Hepatology 50(6), 1750-1755 (2009).
14. Morrill JA, Shrestha M, Grant RW. Barriers to the treatment of hepatitis C. Patient, provider, and system factors. J. Gen. Intern. Med. 20(8), 754-758 (2005). (Pubitemid 41141009)
15. Liu S, Cipriano LE, Holodniy M, Owens DK, Goldhaber-Fiebert JD. New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis. Ann. Intern. Med. 156(4), 279-290 (2012).
16. Thomas DL, Seeff LB. Natural history of hepatitis C. Clin. Liver Dis. 9(3), 383-398, vi (2005). (Pubitemid 40968202)
17. Ward JW, Averhoff FM, Koh HK. World Hepatitis Day: a new era for hepatitis Control. Lancet 378(9791), 552-553 (2011).
18. Okie S. Fighting HIV - lessons from Brazil. N. Engl. J. Med. 354(19), 1977-1981 (2006).
19. Bukh J, Miller RH, Purcell RH. Genetic heterogeneity of hepatitis C virus: quasispecies and genotypes. Semin. Liver Dis. 15(1), 41-63 (1995).
20. Simmonds P. Genetic diversity and evolution of hepatitis C virus - 15 years on. J. Gen. Virol. 85(Pt 11), 3173-3188 (2004). (Pubitemid 39445434)
21. Murray CL, Rice CM. Turning hepatitis C into a real virus. Annu. Rev. Microbiol. 65, 307-327 (2011).
22. Welsch C, Jesudian A, Zeuzem S, Jacobson I. New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives. Gut 61(Suppl. 1), i36-i46 (2012).
23. Lindenbach BD, Evans MJ, Syder AJ et al. Complete replication of hepatitis C virus in cell culture. Science 309(5734), 623-626 (2005). (Pubitemid 41033648)
24. Bartosch B, Dubuisson J, Cosset FL. Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J. Exp. Med. 197(5), 633-642 (2003). (Pubitemid 36314658)
25. Hsu M, Zhang J, Flint M et al. Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles. Proc. Natl Acad. Sci. USA 100(12), 7271-7276 (2003). (Pubitemid 36706428)
26. Yu MY, Bartosch B, Zhang P et al. Neutralizing antibodies to hepatitis C virus (HCV) in immune globulins derived from anti-HCV-positive plasma. Proc. Natl Acad. Sci. USA 101(20), 7705-7710 (2004). (Pubitemid 38658093)
27. Afdhal NH. The natural history of hepatitis C. Semin. Liver Dis. 24(Suppl. 2), 3-8 (2004). (Pubitemid 39180700)
28. Thimme R, Oldach D, Chang KM, Steiger C, Ray SC, Chisari FV. Determinants of viral clearance and persistence during acute hepatitis C virus infection. J. Exp. Med. 194(10), 1395-1406 (2001). (Pubitemid 33081515)
29. Thimme R, Bukh J, Spangenberg HC et al. Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease. Proc. Natl Acad. Sci. USA 99(24), 15661-15668 (2002). (Pubitemid 35403988)
30. Lechner F, Wong DK, Dunbar PR et al. Analysis of successful immune responses in persons infected with hepatitis C virus. J. Exp. Med. 191(9), 1499-1512 (2000). (Pubitemid 30257347)
31. Lauer GM, Barnes E, Lucas M et al. High resolution analysis of cellular immune responses in resolved and persistent hepatitis C virus infection. Gastroenterology 127(3), 924-936 (2004). (Pubitemid 39208424)
32. Urbani S, Amadei B, Fisicaro P et al. Outcome of acute hepatitis C is related to virus-specific CD4 function and maturation of antiviral memory CD8 responses. Hepatology 44(1), 126-139 (2006). (Pubitemid 44049146)
33. Shoukry NH, Grakoui A, Houghton M et al. Memory CD8+ T cells are required for protection from persistent hepatitis C virus infection. J. Exp. Med. 197(12), 1645-1655 (2003). (Pubitemid 36745340)
34. Grakoui A, Shoukry NH, Woollard DJ et al. HCV persistence and immune evasion in the absence of memory T cell help. Science 302(5645), 659-662 (2003). (Pubitemid 37310924)
35. Farci P, Alter HJ, Govindarajan S et al. Lack of protective immunity against reinfection with hepatitis C virus. Science 258(5079), 135-140 (1992).
36. Weiner AJ, Paliard X, Selby MJ et al. Intrahepatic genetic inoculation of hepatitis C virus RNA confers cross-protective immunity. J. Virol. 75(15), 7142-7148 (2001). (Pubitemid 32641602)
37. Bassett SE, Guerra B, Brasky K et al. Protective immune response to hepatitis C virus in chimpanzees rechallenged following clearance of primary infection. Hepatology 33(6), 1479-1487 (2001). (Pubitemid 32496985)
38. Major ME, Mihalik K, Puig M et al. Previously infected and recovered chimpanzees exhibit rapid responses that control hepatitis C virus replication upon rechallenge. J. Virol. 76(13), 6586-6595 (2002). (Pubitemid 34633524)
39. Bukh J, Thimme R, Meunier JC et al. Previously infected chimpanzees are not consistently protected against reinfection or persistent infection after reexposure to the identical hepatitis C virus strain. J. Virol. 82(16), 8183-8195 (2008).
40. Mehta SH, Cox A, Hoover DR et al. Protection against persistence of hepatitis C. Lancet 359(9316), 1478-1483 (2002). (Pubitemid 34457766)
41. Osburn WO, Fisher BE, Dowd KA et al. Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection. Gastroenterology 138(1), 315-324 (2010).
42. Wedemeyer H, He XS, Nascimbeni M et al. Impaired effector function of hepatitis C virus-specific CD8+ T cells in chronic hepatitis C virus infection. J. Immunol. 169(6), 3447-3458 (2002). (Pubitemid 35013196)
43. Gerlach JT, Diepolder HM, Jung MC et al. Recurrence of hepatitis C virus after loss ofvirus-specific CD4(+) T-cell response in acute hepatitis C. Gastroenterology 117(4), 933-941 (1999). (Pubitemid 29468237)
44. Pestka JM, Zeisel MB, Bläser E et al. Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C. Proc. Natl Acad. Sci. USA 104(14), 6025-6030 (2007). (Pubitemid 47175652)
45. von Hahn T, Yoon JC, Alter H et al. Hepatitis C virus continuously escapes from neutralizing antibody and T-cell responses during chronic infection in vivo. Gastroenterology 132(2), 667-678 (2007). (Pubitemid 46274668)
46. Zeisel MB, Cosset FL, Baumert TF. Host neutralizing responses and pathogenesis of hepatitis C virus infection. Hepatology 48(1), 299-307 (2008). (Pubitemid 351975554)
47. Meunier JC, Russell RS, Goossens V et al. Isolation and characterization of broadly neutralizing human monoclonal antibodies to the e1 glycoprotein of hepatitis C virus. J. Virol. 82(2), 966-973 (2008).
48. Perotti M, Mancini N, Diotti RA et al. Identification of a broadly cross-reacting and neutralizing human monoclonal antibody directed against the hepatitis C virus E2 protein. J. Virol. 82(2), 1047-1052 (2008).
49. Johansson DX, Voisset C, Tarr AW et al. Human combinatorial libraries yield rare antibodies that broadly neutralize hepatitis C virus. Proc. Natl Acad. Sci. USA 104(41), 16269-16274 (2007). (Pubitemid 350099395)
50. Law M, Maruyama T, Lewis J et al. Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. Nat. Med. 14(1), 25-27 (2008).
51. Bigger CB, Brasky KM, Lanford RE. DNA microarray analysis of chimpanzee liver during acute resolving hepatitis C virus infection. J. Virol. 75(15), 7059-7066 (2001). (Pubitemid 32641593)
52. Su AI, Pezacki JP, Wodicka L et al. Genomic analysis of the host response to hepatitis C virus infection. Proc. Natl Acad. Sci. USA 99(24), 15669-15674 (2002). (Pubitemid 35403989)
53. Dustin LB, Rice CM. Flying under the radar: the immunobiology of hepatitis C. Annu. Rev. Immunol. 25, 71-99 (2007). (Pubitemid 46697903)
54. Suppiah V, Moldovan M, Ahlenstiel G et al. IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy. Nat. Genet. 41(10), 1100-1104 (2009).
55. Tanaka Y, Nishida N, Sugiyama M et al. Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C. Nat. Genet. 41(10), 1105-1109 (2009).
56. Thomas DL, Thio CL, Martin MP et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 461(7265), 798-801 (2009).
57. Ge D, Fellay J, Thompson AJ et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461(7262), 399-401 (2009).
58. Khakoo SI, Thio CL, Martin MP et al. HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science 305(5685), 872-874 (2004). (Pubitemid 39038423)
59. Suppiah V, Gaudieri S, Armstrong NJ et al.; International Hepatitis C Genetics Consortium (IHCGC). IL28B, HLA-C, and KIR variants additively predict response to therapy in chronic hepatitis C virus infection in a European Cohort: a cross-sectional study. PLoS Med. 8(9), e1001092 (2011).
60. Ip PP, Nijman HW, Wilschut J, Daemen T. Therapeutic vaccination against chronic hepatitis C virus infection. Antiviral Res. 96(1), 36-50 (2012).
61. Bowen DG, Walker CM. Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature 436(7053), 946-952 (2005). (Pubitemid 41191670)
62. Li H, Stoddard MB, Wang S et al. Elucidation of hepatitis C virus transmission and early diversification by single genome sequencing. PLoS Pathog. 8(8), e1002880 (2012).
63. Choo QL, Kuo G, Ralston R et al. Vaccination of chimpanzees against infection by the hepatitis C virus. Proc. Natl Acad. Sci. USA 91(4), 1294-1298 (1994). (Pubitemid 24058997)
64. Forns X, Payette PJ, Ma X et al. Vaccination of chimpanzees with plasmid DNA encoding the hepatitis C virus (HCV) envelope E2 protein modified the infection after challenge with homologous monoclonal HCV. Hepatology 32(3), 618-625 (2000).
65. Frey SE, Houghton M, Coates S et al. Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults. Vaccine 28(38), 6367-6373 (2010).
66. Stamataki Z, Coates S, Abrignani S, Houghton M, McKeating JA. Immunization of human volunteers with hepatitis C virus envelope glycoproteins elicits antibodies that cross-neutralize heterologous virus strains. J. Infect. Dis. 204(5), 811-813 (2011).
67. Potter JA, Owsianka AM, Jeffery N et al. Toward a hepatitis C virus vaccine: the structural basis of hepatitis C virus neutralization by AP33, a broadly neutralizing antibody. J. Virol. 86(23), 12923-12932 (2012).
68. Keck ZY, Xia J, Wang Y et al. Human monoclonal antibodies to a novel cluster of conformational epitopes on HCV E2 with resistance to neutralization escape in a genotype 2a isolate. PLoS Pathog. 8(4), e1002653 (2012).
69. Yutani S, Yamada A, Yoshida K et al. Phase I clinical study of a personalized peptide vaccination for patients infected with hepatitis C virus (HCV) 1b who failed to respond to interferon-based therapy. Vaccine 25(42), 7429-7435 (2007). (Pubitemid 47484009)
70. Klade CS, Wedemeyer H, Berg T et al. Therapeutic vaccination of chronic hepatitis C nonresponder patients with the peptide vaccine IC41. Gastroenterology 134(5), 1385-1395 (2008).
71. Habersetzer F, Honnet G, Bain C et al. A poxvirus vaccine is safe, induces T-cell responses, and decreases viral load in patients with chronic hepatitis C. Gastroenterology 141(3), 890.e1-899.e1 (2011).
72. Feinstone SM, Hu DJ, Major ME. Prospects for prophylactic and therapeutic vaccines against hepatitis C virus. Clin. Infect. Dis. 55(Suppl. 1), S25-S32 (2012).
73. Sette A, Rappuoli R. Reverse vaccinology: developing vaccines in the era of genomics. Immunity 33(4), 530-541 (2010).
74. Santolaya ME, O'Ryan ML, Valenzuela MT et al.; V72P10 Meningococcal B Adolescent Vaccine Study group. Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a Phase 2b/3 randomised, observer-blind, placebo-controlled study. Lancet 379(9816), 617-624 (2012).
75. Scheid JF, Mouquet H, Feldhahn N et al. Broad diversity of neutralizing antibodies isolated from memory B cells in HIVinfected individuals. Nature 458(7238), 636-640 (2009).
76. Walker LM, Huber M, Doores KJ et al.; Protocol G Principal Investigators. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 477(7365), 466-470 (2011).
77. Wu X, Yang ZY, Li Y et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 329(5993), 856-861 (2010).
78. Walker LM, Phogat SK, Chan-Hui PY et al.; Protocol G Principal Investigators. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326(5950), 285-289 (2009).
79. Burton DR, Pyati J, Koduri R et al. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 266(5187), 1024-1027 (1994). (Pubitemid 24373715)
80. Muster T, Steindl F, Purtscher M et al. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J. Virol. 67(11), 6642-6647 (1993). (Pubitemid 23309131)
81. Buchacher A, Predl R, Strutzenberger K et al. Generation of human monoclonal antibodies against HIV-1 proteins; electrofusion and Epstein-Barr virus transformation for peripheral blood lymphocyte immortalization. AIDS Res. Hum. Retroviruses 10(4), 359-369 (1994). (Pubitemid 24141210)
82. Trkola A, Purtscher M, Muster T et al. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J. Virol. 70(2), 1100-1108 (1996). (Pubitemid 26029030)
83. Van Regenmortel MH. Requirements for empirical immunogenicity trials, rather than structure-based design, for developing an effective HIV vaccine. Arch. Virol. 157(1), 1-20 (2012).
84. Virgin HW, Walker BD. Immunology and the elusive AIDS vaccine. Nature 464(7286), 224-231 (2010).
85. Whidby J, Mateu G, Scarborough H, Demeler B, Grakoui A, Marcotrigiano J. Blocking hepatitis C virus infection with recombinant form of envelope protein 2 ectodomain. J. Virol. 83(21), 11078-11089 (2009).
86. Krey T, d'Alayer J, Kikuti CM et al. The disulfide bonds in glycoprotein E2 of hepatitis C virus reveal the tertiary organization of the molecule. PLoS Pathog. 6(2), e1000762 (2010).
87. Giang E, Dorner M, Prentoe JC et al. Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus. Proc. Natl Acad. Sci. USA 109(16), 6205-6210 (2012).
88. Owsianka A, Tarr AW, Juttla VS et al. Monoclonal antibody AP33 defines a broadly neutralizing epitope on the hepatitis C virus E2 envelope glycoprotein. J. Virol. 79(17), 11095-11104 (2005). (Pubitemid 41170650)
89. Broering TJ, Garrity KA, Boatright NK et al. Identification and characterization of broadly neutralizing human monoclonal antibodies directed against the E2 envelope glycoprotein of hepatitis C virus. J. Virol. 83(23), 12473-12482 (2009).
90. Schofield DJ, Bartosch B, Shimizu YK et al. Human monoclonal antibodies that react with the E2 glycoprotein of hepatitis C virus and possess neutralizing activity. Hepatology 42(5), 1055-1062 (2005). (Pubitemid 43112672)
91. Keck ZY, Li TK, Xia J et al. Definition of a conserved immunodominant domain on hepatitis C virus E2 glycoprotein by neutralizing human monoclonal antibodies. J. Virol. 82(12), 6061-6066 (2008). (Pubitemid 351822282)
92. Sabo MC, Luca VC, Prentoe J et al. Neutralizing monoclonal antibodies against hepatitis C virus E2 protein bind discontinuous epitopes and inhibit infection at a postattachment step. J. Virol. 85(14), 7005-7019 (2011).
93. Fischer W, Perkins S, Theiler J et al. Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants. Nat. Med. 13(1), 100-106 (2007). (Pubitemid 46067393)
94. Korber BT, Letvin NL, Haynes BF. T-cell vaccine strategies for human immunodeficiency virus, the virus with a thousand faces. J. Virol. 83(17), 8300-8314 (2009).
95. Yusim K, Fischer W, Yoon H et al. Genotype 1 and global hepatitis C T-cell vaccines designed to optimize coverage of genetic diversity. J. Gen. Virol. 91(Pt 5), 1194-1206 (2010).
96. Barouch DH, O'Brien KL, Simmons NL et al. Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys. Nat. Med. 16(3), 319-323 (2010).
97. Colloca S, Barnes E, Folgori A et al. Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species. Sci. Transl. Med. 4(115), 115ra2 (2012).
98. O'Hara GA, Duncan CJ, Ewer KJ et al. Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector. J. Infect. Dis. 205(5), 772-781 (2012).
99. Sheehy SH, Duncan CJ, Elias SC et al. Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors. PLoS ONE 7(2), e31208 (2012).
100. Zhou Y, Zhang Y, Yao Z, Moorman JP, Jia Z. Dendritic cell-based immunity and vaccination against hepatitis C virus infection. Immunology 136(4), 385-396 (2012).
101. Trumpfheller C, Longhi MP, Caskey M et al. Dendritic cell-targeted protein vaccines: a novel approach to induce T-cell immunity. J. Intern. Med. 271(2), 183-192 (2012).
102. Strickland GT, El-Kamary SS, Klenerman P, Nicosia A. Hepatitis C vaccine: supply and demand. Lancet Infect. Dis. 8(6), 379-386 (2008). (Pubitemid 351697805)
103. Féray C, Gigou M, Samuel D et al. Incidence of hepatitis C in patients receiving different preparations of hepatitis B immunoglobulins after liver transplantation. Ann. Intern. Med. 128(10), 810-816 (1998). (Pubitemid 28267713)
104. Davis GL. Hepatitis C immune globulin to prevent HCV recurrence after liver transplantation: chasing windmills? Liver Transpl. 12(9), 1317-1319 (2006). (Pubitemid 44405117)
105. Balazs AB, Chen J, Hong CM, Rao DS, Yang L, Baltimore D. Antibody-based protection against HIV infection by vectored immunoprophylaxis. Nature 481(7379), 81-84 (2012).
106. Ohira M, Ishiyama K, Tanaka Y et al. Adoptive immunotherapy with liver allograft-derived lymphocytes induces anti-HCV activity after liver transplantation in humans and humanized mice. J. Clin. Invest. 119(11), 3226-3235 (2009).
107. Doskali M, Tanaka Y, Ohira M et al. Possibility of adoptive immunotherapy with peripheral blood-derived CD3-CD56+ and CD3+CD56+ cells for inducing antihepatocellular carcinoma and antihepatitis C virus activity. J. Immunother. 34(2), 129-138 (2011).
108. Jameson SC. Maintaining the norm: T-cell homeostasis. Nat. Rev. Immunol. 2(8), 547-556 (2002). (Pubitemid 37328730)
109. Yamazaki T, Akiba H, Iwai H et al. Expression of programmed death 1 ligands by murine T cells and APC. J. Immunol. 169(10), 5538-5545 (2002). (Pubitemid 35291652)
110. Sánchez-Fueyo A, Tian J, Picarella D et al. Tim-3 inhibits T helper type 1-mediated auto- and alloimmune responses and promotes immunological tolerance. Nat. Immunol. 4(11), 1093-1101 (2003). (Pubitemid 37428037)
111. Freeman GJ, Long AJ, Iwai Y et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exp. Med. 192(7), 1027-1034 (2000).
112. Sabatos CA, Chakravarti S, Cha E et al. Interaction of Tim-3 and Tim-3 ligand regulates T helper type 1 responses andinduction of peripheral tolerance. Nat. Immunol. 4(11), 1102-1110 (2003). (Pubitemid 37428038)
113. Sakaguchi S, Miyara M, Costantino CM, Hafler DA. FOXP3+ regulatory T cells in the human immune system. Nat. Rev. Immunol. 10(7), 490-500 (2010).
114. McMahan RH, Golden-Mason L, Nishimura MI et al. Tim-3 expression on PD-1+ HCV-specific human CTLs is associated with viral persistence, and its blockade restores hepatocyte-directed in vitro cytotoxicity. J. Clin. Invest. 120(12), 4546-4557 (2010).
115. Wakita T, Pietschmann T, Kato T et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat. Med. 11(7), 791-796 (2005). (Pubitemid 41021213)
116. Zhong J, Gastaminza P, Cheng G et al. Robust hepatitis C virus infection in vitro. Proc. Natl Acad. Sci. USA 102(26), 9294-9299 (2005). (Pubitemid 40923557)
117. Owsianka AM, Tarr AW, Keck ZY et al. Broadly neutralizing human monoclonal antibodies to the hepatitis C virus E2 glycoprotein. J. Gen. Virol. 89(Pt 3), 653-659 (2008).
118. Haberstroh A, Schnober EK, Zeisel MB et al. Neutralizing host responses in hepatitis C virus infection target viral entry at postbinding steps and membrane fusion. Gastroenterology 135(5), 1719.e1-1728.e1 (2008).
119. Uebelhoer L, Han JH, Callendret B et al. Stable cytotoxic T cell escape mutation in hepatitis C virus is linked to maintenance of viral fitness. PLoS Pathog. 4(9), e1000143 (2008).
120. Pietschmann T, Kaul A, Koutsoudakis G et al. Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras. Proc. Natl Acad. Sci. USA 103(19), 7408-7413 (2006). (Pubitemid 43727846)
121. Gottwein JM, Scheel TK, Jensen TB et al. Development and characterization of hepatitis C virus genotype 1-7 cell culture systems: role of CD81 and scavenger receptor class B type I and effect of antiviral drugs. Hepatology 49(2), 364-377 (2009).
122. Jensen TB, Gottwein JM, Scheel TK, Hoegh AM, Eugen-Olsen J, Bukh J. Highly efficient JFH1-based cell-culture system for hepatitis C virus genotype 5a: failure of homologous neutralizing-antibody treatment to control infection. J. Infect. Dis. 198(12), 1756-1765 (2008).
123. Scheel TK, Gottwein JM, Jensen TB et al. Development of JFH1-based cell culture systems for hepatitis C virus genotype 4a and evidence for cross-genotype neutralization. Proc. Natl Acad. Sci. USA 105(3), 997-1002 (2008). (Pubitemid 351282070)
124. Folgori A, Capone S, Ruggeri L et al. A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees. Nat. Med. 12(2), 190-197 (2006). (Pubitemid 43214745)
125. Washburn ML, Bility MT, Zhang L et al. A humanized mouse model to study hepatitis C virus infection, immune response, and liver disease. Gastroenterology 140(4), 1334-1344 (2011).
126. Koutsoudakis G, Kaul A, Steinmann E et al. Characterization of the early steps of hepatitis C virus infection by using luciferase reporter viruses. J. Virol. 80(11), 5308-5320 (2006).
127. Barth H, Schafer C, Adah MI et al. Cellular binding of hepatitis C virus envelope glycoprotein E2 requires cell surface heparan sulfate. J. Biol. Chem. 278(42), 41003-41012 (2003). (Pubitemid 37280923)
128. Molina S, Castet V, Fournier-Wirth C et al. The low-density lipoprotein receptor plays a role in the infection of primary human hepatocytes by hepatitis C virus. J. Hepatol. 46(3), 411-419 (2007). (Pubitemid 46201721)
129. Agnello V, Abel G, Elfahal M, Knight GB, Zhang QX. Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor. Proc. Natl Acad. Sci. USA 96(22), 12766-12771 (1999). (Pubitemid 29513577)
130. Monazahian M, Böhme I, Bonk S et al. Low density lipoprotein receptor as a candidate receptor for hepatitis C virus. J. Med. Virol. 57(3), 223-229 (1999). (Pubitemid 29069727)
131. Owen DM, Huang H, Ye J, Gale M Jr. Apolipoprotein E on hepatitis C virion facilitates infection through interaction with low-density lipoprotein receptor. Virology 394(1), 99-108 (2009).
132. Pileri P, Uematsu Y, Campagnoli S et al. Binding of hepatitis C virus to CD81. Science 282(5390), 938-941 (1998). (Pubitemid 28507525)
133. Evans MJ, von Hahn T, Tscherne DM et al. Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature 446(7137), 801-805 (2007). (Pubitemid 46582027)
134. Ploss A, Evans MJ, Gaysinskaya VA et al. Human occludin is a hepatitis C virus entry factor required for infection of mouse cells. Nature 457(7231), 882-886 (2009).
135. Liu S, Yang W, Shen L, Turner JR, Coyne CB, Wang T. Tight junction proteins claudin-1 and occludin control hepatitis C virus entry and are downregulated during infection to prevent superinfection. J. Virol. 83(4), 2011-2014 (2009).
136. Sainz B Jr, Barretto N, Martin DN et al. Identification of the Niemann-Pick C1-like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor. Nat. Med. 18(2), 281-285 (2012).
137. Lupberger J, Zeisel MB, Xiao F et al. EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. Nat. Med. 17(5), 589-595 (2011).
138. Ploss A, Evans MJ. Hepatitis C virus host cell entry. Curr. Opin. Virol. 2(1), 14-19 (2012).
139. Bitzegeio J, Bankwitz D, Hueging K et al. Adaptation of hepatitis C virus to mouse CD81 permits infection of mouse cells in the absence of human entry factors. PLoS Pathog. 6, e1000978 (2010).
140. Mestas J, Hughes CC. Of mice and not men: differences between mouse and human immunology. J. Immunol. 172(5), 2731-2738 (2004). (Pubitemid 38263654)
141. Waterston RH, Lander ES, Sulston JE. On the sequencing of the human genome. Proc. Natl Acad. Sci. USA 99(6), 3712-3716 (2002). (Pubitemid 34252171)
142. Abe K, Kurata T, Teramoto Y, Shiga J, Shikata T. Lack of susceptibility of various primates and woodchucks to hepatitis C virus. J. Med. Primatol. 22(7-8), 433-434 (1993).
143. Patel MR, Loo YM, Horner SM, Gale M Jr, Malik HS. Convergent evolution of escape from hepaciviral antagonism in primates. PLoS Biol. 10(3), e1001282 (2012).
144. Hatziioannou T, Ambrose Z, Chung NP et al. A macaque model of HIV-1 infection. Proc. Natl Acad. Sci. USA 106(11), 4425-4429 (2009).
145. Hatziioannou T, Princiotta M, Piatak M Jr et al. Generation of simian-tropic HIV-1 by restriction factor evasion. Science 314(5796), 95 (2006). (Pubitemid 44547747)
146. Mercer DF, Schiller DE, Elliott JF et al. Hepatitis C virus replication in mice with chimeric human livers. Nat. Med. 7(8), 927-933 (2001). (Pubitemid 32756430)
147. Meuleman P, Libbrecht L, De Vos R et al. Morphological and biochemical characterization of a human liver in a uPA-SCID mouse chimera. Hepatology 41(4), 847-856 (2005). (Pubitemid 40462948)
148. Azuma H, Paulk N, Ranade A et al. Robust expansion of human hepatocytes in Fah-/-/ Rag2-/-/Il2rg-/- mice. Nat. Biotechnol. 25(8), 903-910 (2007). (Pubitemid 47236918)
149. Bissig KD, Le TT, Woods NB, Verma IM. Repopulation of adult and neonatal mice with human hepatocytes: a chimeric animal model. Proc. Natl Acad. Sci. USA 104(51), 20507-20511 (2007).
150. Bissig KD, Wieland SF, Tran P et al. Human liver chimeric mice provide a model for hepatitis B and C virus infection and treatment. J. Clin. Invest. 120(3), 924-930 (2010).
151. Dorner M, Horwitz JA, Robbins JB et al. A genetically humanized mouse model for hepatitis C virus infection. Nature 474(7350), 208-211 (2011).
152. Perz JF, Farrington LA, Pecoraro C, Hutin YJF, Armstrong GL. Estimated global prevalence of hepatitis C virus infection. Presented at: 42nd Annual Meeting of the Infectious Diseases Society of America. Boston, MA, USA, 30 September- 3 October 2004.
153. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann. Intern. Med. 144(10), 705-714 (2006). (Pubitemid 46780630)
154. Villano SA, Vlahov D, Nelson KE, Cohn S, Thomas DL. Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection. Hepatology 29(3), 908-914 (1999). (Pubitemid 29109609)
155. ClinicalTrials.gov Identifier: NCT00500747. www.clinicaltrials.gov
156. ClinicalTrials.gov Identifier: NCT01436357. www.clinicaltrials.gov
157. ClinicalTrials.gov Identifier: NCT01070407. www.clinicaltrials.gov
158. NIH. Grants and funding. http://grants.nih.gov/grants/guide/ notice-files/NOT-OD-12-025.html
159. ClinicalTrials.gov. www.clinicaltrials.gov